Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO").
Location: Sweden, Solna kommun
Employees: 11-50
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Midroc New... | midroc.se |
| - | Chalmers V... | chalmersve... |
Mentions in press and media 9
| Date | Title | Description | Source |
| 12.04.2024 | Notice of Annual General Meeting in Moberg Pharma AB (publ) | Notice of Annual General Meeting in Moberg Pharma AB (publ) Fri, Apr 12, 2024 08:00 CET Report this ... | news.cisio... |
| 27.02.2023 | Promore Pharma Reaches the Clean File Milestone in its Phase... | STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2023 / Promore Pharma PROMO (FRA:8T0) STOCKHOLM, 27 Fe... | einpresswi... |
| 24.11.2022 | Invitation to Conference Call Regarding Promore Pharma’s Int... | STOCKHOLM, SE / ACCESSWIRE / November 24, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 24 N... | accesswire... |
| 23.11.2022 | Nomination Committee Appointed for the Annual General Meetin... | STOCKHOLM, SE / ACCESSWIRE / November 23, 2022 / Promore Pharma PROMO (FRA:8T0) STOCKHOLM, 23 Novemb... | einpresswi... |
| 17.05.2022 | Report from the Annual General Meeting of Promore Pharma AB ... | STOCKHOLM, SWEDEN / ACCESSWIRE / May 17, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0) Promore Pharma ... | accesswire... |
| 13.05.2022 | Invitation to Conference Call Regarding Promore Pharma’s Int... | STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 13 Ma... | accesswire... |
| 12.04.2022 | Notice of Annual General Meeting Promore Pharma AB (publ) | STOCKHOLM, SWEDEN / ACCESSWIRE / April 12, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0) The Annual Gen... | accesswire... |
| 28.04.2021 | PROMORE PHARMA AB (PUBL) Promore Pharma AB : (publ) - NOTIC... | Unofficial English translation for information purposes only. If there are differences between the E... | marketscre... |
| 07.05.2018 | Allergan aesthetics chief David Moatazedi becomes CEO ... | David Moatazedi → Allergan aesthetics chief David Moatazedi is leaving to take the helm of Ev... | endpts.com... |